Related Experiment Video
Updated: Nov 22, 2025
07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
622
Untapped Potential: Therapeutically Targeting Eicosanoids and Endocannabinoids in the Lung
Lael M Yonker1,2,3, Juliana Barrios2,3, Hongmei Mou2,3
1Massachusetts General Hospital, Department of Pediatrics, Pulmonary Division, Boston, Massachusetts, USA.
Clinical Pharmacology and Therapeutics
|January 10, 2021
Summary
Airway inflammation involves immune cells and lipid mediators like eicosanoids and endocannabinoids. Understanding these mediators is key to developing therapies for lung conditions such as cystic fibrosis.
Area of Science:
- Lipid mediator synthesis and function in airway inflammation and resolution.
Background:
- Airway inflammation involves immune cell recruitment, potentially causing lung tissue damage.
- Resolution of inflammation is mediated by specific factors, often lipid mediators.
- Eicosanoids and endocannabinoids are key lipid mediator classes with overlapping functions.
Purpose of the Study:
- To summarize major bioactive eicosanoids and endocannabinoids.
- To discuss challenges in studying these lipid mediators.
- To review their roles in modulating airway inflammation and resolution, with a focus on cystic fibrosis.
Main Methods:
- Literature review of eicosanoids and endocannabinoids.
- Analysis of their synthetic pathways and functions.
- Examination of therapeutic strategies targeting these mediators.
Main Results:
- Eicosanoids and endocannabinoids are crucial for both inflammation and resolution processes.
- Shared synthetic enzymes highlight the interconnectedness of these lipid mediator pathways.
- Therapeutic interventions targeting these mediators show potential for managing airway inflammation.
Conclusions:
- Lipid mediators are central to airway inflammation and resolution.
- Targeting eicosanoids and endocannabinoids offers therapeutic avenues for lung diseases.
- Further research is needed to overcome challenges in studying and utilizing these mediators, especially in cystic fibrosis.
More Related Videos
Related Concept Videos
01:17Drugs Used in Lower Respiratory Disorders: Overview
830
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
830
01:19Antiasthma Drugs: Leukotriene Modifiers
1.5K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.5K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
287
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
287
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
326
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
326
01:26COPD: Management Using Bronchodilators and Corticosteroids
551
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
551
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.9K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.9K